Kras Co-mutations lead to resistance to mutant TP53 targeted therapy in mouse models of spontaneous non-small cell lung cancer.

被引：0
|
作者：
Costa, David T. [1 ]
Grier, Shaylyn [1 ]
Perez, Melanie [1 ]
Gao, Li [1 ]
Villalona-Calero, Miguel A. [2 ]
Duan, Wenrui [1 ]
机构：
[1] Florida Int Univ, Miami, FL USA
[2] City Hope Natl Med Ctr, Med Ctr, Duarte, CA USA
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6184
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Impact of TP53/KRAS mutations on overall survival of metastatic non-small cell lung cancer patients (pts) treated with systemic first-line therapy
    Novella, S. Rubio
    Cobo, A.
    Montes, A.
    Lopez, J. Soler
    Rondan, M. Arnal
    Palanca, S. Noguera
    Tena, I.
    Miguel, J.
    Navarro, B.
    Domingo, I.
    Esteban, S. Cases
    Diaz, M.
    Andrade, P.
    Rosello, E.
    Santander, J. R. Lazaro
    Estelles, D. Lorente
    Hernandez, A. Sanchez
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S80 - S81
  • [42] Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer
    Suzawa, Ken
    Offin, Michael
    Lu, Daniel
    Kurzatkowski, Christopher
    Vojnic, Morana
    Smith, Roger S.
    Sabari, Joshua K.
    Tai, Huichun
    Mattar, Marissa
    Khodos, Inna
    de Stanchina, Elisa
    Rudin, Charles M.
    Kris, Mark G.
    Arcila, Maria E.
    Lockwood, William W.
    Drilon, Alexander
    Ladanyi, Marc
    Somwar, Romel
    [J]. CLINICAL CANCER RESEARCH, 2019, 25 (04) : 1248 - 1260
  • [43] Impact of TP53 and KRAS mutations on cisplatin-based adjuvant chemotherapy in non-small-cell lung cancer
    Ma, X.
    Brambilla, E.
    Soria, J. C.
    Dunant, A.
    Vataire, A. L.
    Hainaut, P.
    [J]. EJC SUPPLEMENTS, 2008, 6 (09): : 104 - 104
  • [44] TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy-EGFR mutated non-small cell lung cancer IV patients treated with osimertinib
    Roeper, Julia
    Christopoulos, Petros
    Falk, Markus
    Heukamp, Lukas C.
    Tiemann, Markus
    Stenzinger, Albrecht
    Thomas, Michael
    Griesinger, Frank
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (01) : 4 - +
  • [45] MUTANT-TARGETED THERAPY FOR NON-SMALL CELL LUNG CANCER
    Sorbera, L. A.
    Tremosa, L.
    Dulsat, C.
    [J]. DRUGS OF THE FUTURE, 2016, 41 (11) : 671 - 676
  • [46] Evaluation of EGFR, KRAS, and TP53 mutations as predictive of disease recurrence in resected early non-small cell lung carcinomas (NSCLCs)
    Bar J.
    Damianovich M.
    Siloni G.H.
    Dar E.
    Cohen Y.
    Zadok O.
    Cohen Y.
    Perelman M.
    Barshack I.
    Yarden R.I.
    Simansky D.
    Ben Nun A.
    Onn A.
    [J]. memo - Magazine of European Medical Oncology, 2014, 7 (1) : 10 - 15
  • [47] KRAS-targeted therapy in the treatment of non-small cell lung cancer
    Yun, Jina
    Nakagawa, Reid
    Tham, Kenneth
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, : 422 - 430
  • [48] Efficacy of immunotherapy as second-line or later-line therapy and prognostic significance of KRAS or TP53 mutations in advanced non-small cell lung cancer patients
    Liu, Jingya
    Gao, Jianing
    [J]. EUROPEAN JOURNAL OF CANCER PREVENTION, 2023, 32 (06) : 590 - 599
  • [49] Non-small cell lung cancer - mutations, targeted and combination therapy
    Kutkowska, Justyna
    Porebska, Irena
    Rapak, Andrzej
    [J]. POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ, 2017, 71 : 431 - 445
  • [50] The significance of co-mutations in EGFR-mutated non-small cell lung cancer: Optimizing the efficacy of targeted therapies?
    Pezzuto, Federica
    Hofman, Veronique
    Bontoux, Christophe
    Fortarezza, Francesco
    Lunardi, Francesca
    Calabrese, Fiorella
    Hofman, Paul
    [J]. LUNG CANCER, 2023, 181
12345